We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01033851
First Posted: December 17, 2009
Last Update Posted: June 4, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Center for Complementary and Integrative Health (NCCIH)
Information provided by (Responsible Party):
Elizabeth A. Hoge, MD, Massachusetts General Hospital
  Purpose
Current therapies for Generalized Anxiety Disorder (GAD) have limited effectiveness. This study measures the efficacy of two different approaches to reducing anxiety and stress. One approach uses education, nutrition, exercise, and time management training, and another uses mindfulness meditation and yoga, which is taught as part of the Mindfulness-based stress reduction (MBSR) course, an 8-week manualized mindfulness intervention. We hypothesize that the two approaches will reduce anxiety in individuals with GAD in different ways. We will measure changes in stress hormones associated with these changes.

Condition Intervention Phase
Generalized Anxiety Disorder Behavioral: Mindfulness Based Stress Reduction Behavioral: Stress Management Education Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Stress Reduction Techniques and Anxiety: Therapeutic and Neuroendocrine Effects

Resource links provided by NLM:


Further study details as provided by Elizabeth A. Hoge, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • Active Symptoms of Generalized Anxiety Disorder [ Time Frame: 2 months ]
    The Hamilton Anxiety Scale (HAMA) was defined as the primary anxiety outcome variable. This scale has 14 items describing symptoms of anxiety, each answered on a 0-4 scale, with 0 for a single question generally representing no symptoms, and 4 representing severe levels of the symptom. The total score is calculated by adding all the items together, for a possible total score of 0 to 56.


Secondary Outcome Measures:
  • Clinical Global Impression of Severity (CGIS) of Anxiety Symptoms. [ Time Frame: 2 months ]
    This is an overal clinical measure of anxiety symptoms after examining and interviewing the patient. The scale is one global item, that scores from 1 (1= not ill at all) to 7 (7= among the most extremely ill).


Enrollment: 89
Study Start Date: March 2008
Study Completion Date: February 2013
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Mindfulness Based Stress Reduction
Mindfulness Based Stress Reduction (MBSR) is an 8-week group intervention that trains participants in mindfulness meditation techniques.
Behavioral: Mindfulness Based Stress Reduction
8 week course
Active Comparator: Stress Management Education
Stress Management Education (SME) is an 8-week group intervention that educates participants about stress physiology and health lifestyle changes.
Behavioral: Stress Management Education
8 week course

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults with generalized anxiety disorder
  • medically healthy

Exclusion Criteria:

  • substance abuse
  • history of other psychiatric diagnoses such as psychosis, Obsessive Compulsive Disorder, PTSD
  • use of certain types of psychotherapy, meditation training, yoga
  • pregnant or lactating women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01033851


Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Center for Complementary and Integrative Health (NCCIH)
Investigators
Principal Investigator: Elizabeth A Hoge, MD Massachusetts General Hospital
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Elizabeth A. Hoge, MD, Assistant Psychiatrist, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01033851     History of Changes
Other Study ID Numbers: 2008-P-000275
5K23AT004432 ( U.S. NIH Grant/Contract )
First Submitted: December 9, 2009
First Posted: December 17, 2009
Results First Submitted: February 21, 2013
Results First Posted: June 11, 2013
Last Update Posted: June 4, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders